EMA Begins Review of Dexamethasone for COVID-19

The EMA’s Committee for Medicinal Products for Human Use is reviewing dexamethasone as a potential treatment for adults with COVID-19 who require respiratory support.

The committee is considering data from the UK’s Recovery trial, which found the drug reduced mortality in patients on mechanical ventilation or receiving oxygen. The study found no benefit in those who did not require oxygen.

The UK approved dexamethasone last month for reducing the risk of death in COVID-19 patients requiring ventilation or oxygen based on the positive results from the Recovery trial.